Pär-Ola Larsson new CEO of CarpoNovum

The board of directors have appointed Pär-Ola Larsson as new CEO of CarpoNovum, starting in April 2022.

Pär-Ola has a long experience working with Healtcare and Medical Service, both in Sweden and internationally. He has studied economics and marketing at the School of Economics in Gothenburg University, and holds an EMBA from Copenhagen Business School (CBS). He also has more than 15 years of experience from Boston Scientific and Johnson & Johnson, doing business development, marketing and sales, and working close to different stapling techniques. Per-Olas most recent position was head of Marketing and Sales at XVIVO Perfusion AB.

Anders Grönberg is now given more time to focus as Chief Medical Officer in CarpoNovum AB. As earlier, attention is on accreditation of surgeons and to lead clinical studies as part of the market introduction. Furthermore, Anders will work to reduce COGS and adapt C-REX for mass production.

Anders Grönberg also continue to hold his position as CEO of CarpoNovum Clinics Ltd, where the intention is to expand the business further.

Anders Grönberg to expand focus on accreditation of surgeons and clinical studies

Anders Grönberg is now given more time to focus as Chief Medical Officer in CarpoNovum AB. As earlier, attention is on accreditation of surgeons and to lead clinical studies as part of the market introduction. Furthermore, Anders will work to reduce COGS and adapt C-REX for mass production.

Anders Grönberg also continue to hold his position as CEO of CarpoNovum Clinics Ltd, where the intention is to expand the business further.

New PMCF Study to start in 2022

In 2022, CarpoNovum will start a European ​Multicenter Post Market Clinical Follow-up study (outside Sweden) on the C-REX® system.​

As part of this we will be hosting workshops throughout the year. These workshops serve a first step for surgeons to get accreditation for use of C-REX® products. ​